Prelude Capital Management, LLC Bluebird Bio, Inc. Transaction History

Prelude Capital Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $83,690 - $219,087	26,653 New	26,653 $84,000
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $76,184 - $142,338	-6,778 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $122,275 - $149,726	6,778 New	6,778 $217,000
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $173,662 - $239,464	-6,315 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $113,342 - $143,981	-3,291 Reduced 34.26%	6,315 $341,000
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $241,612 - $409,546	8,909 Added 1278.19%	9,606 $586,000
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $17,213 - $41,783	-658 Reduced 48.56%	697 $32,000
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $35,126 - $46,129	-748 Reduced 35.57%	1,355 $119,000
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $135,517 - $218,943	2,103 New	2,103 $331,000
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $9,863 - $13,041	-111 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $11,060 - $14,162	111 New	111 $17,000
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $103,756 - $166,903	-1,277 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $73,733 - $116,743	1,277	1,277 $175,000

159

79.5M

525K

634K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $31.6M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.